Lighten up. Press releases have been issued over the last few years specifically to inform of new developments and new innovations in the evolution of the company's R & D. As with any company in this field the farther one progresses the more it becomes aware that there are possibilities that never were considered.

The clinical studies by the Texas entity, a broad range of patent approvals partnered with international complex licensing and distribution contracts which have obviously been negotiated by firms with great credibility and experience, the announcement of the peer review and soon to be published papers are the most positive information released to date.

There was no mention on a possible value expected on the pps by the company from these developments and there should not have been. Just good updated information for the investors.

If you are so disillusioned by where we now stand I would suggest selling and moving on. I have stated before that I am comfortable with the company's position and current status and feel that my long term investment position has never looked more positive.

Instant gratification with something like this is seldom realized but patience is rewarded.